Metalyse® 25 mg (TENECTEPLASE) is available for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage1
Your central destination for practical tools, guidance, and educational materials to support the assessment and management of acute ischaemic stroke.
Designed for busy stroke clinicians, this collection brings together resources to help streamline decision‑making, enhance pathway delivery, and optimise patient care.
PC-GB-112287 April 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).
Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.
